INDAPTUS THERAPEUTICS INC. - COMMON STOCK

Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

08 May 2025 07:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

25 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20

20 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab

18 Mar 2025 07:00:00 By Nasdaq GlobeNewswire

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

13 Mar 2025 06:30:00 By Nasdaq GlobeNewswire

Registration Is Now Open For Tribe Public’s Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics’ CEO On Monday, March 17, 2025

12 Mar 2025 15:15:00 By Nasdaq GlobeNewswire

Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments

04 Mar 2025 07:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit

25 Feb 2025 07:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20

05 Feb 2025 07:00:00 By Nasdaq GlobeNewswire

Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules

13 Jan 2025 07:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

08 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

22 Nov 2024 07:36:14 By Nasdaq GlobeNewswire

Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

11 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

07 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

23 Oct 2024 07:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

22 Oct 2024 07:00:01 By Nasdaq GlobeNewswire

Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

15 Oct 2024 07:00:00 By Nasdaq GlobeNewswire